Endocyte

Endocyte

Pharmaceuticals, Purdue Research Park, West Lafayette, Indiana, 47906, United States, 51-200 Employees

endocyte.com

  • facebook
  • LinkedIn

phone no Phone Number: 76********

Who is ENDOCYTE

Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the personalized treatment of cancer. The company's drug conjugation technology targets therapeutic...

Read More

map
  • Purdue Research Park, West Lafayette, Indiana, 47906, United States Headquarters: Purdue Research Park, West Lafayette, Indiana, 47906, United States
  • 1996 Date Founded: 1996
  • 51-200 Employees: 51-200
  • dollar-icon Revenue: $10 Million to $25 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Pharmaceuticals

SIC SIC Code: 2834 | NAICS Code: 325412 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from ENDOCYTE

Endocyte Org Chart and Mapping

Employees
signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Endocyte

Answer: Endocyte's headquarters are located at Purdue Research Park, West Lafayette, Indiana, 47906, United States

Answer: Endocyte's phone number is 76********

Answer: Endocyte's official website is https://endocyte.com

Answer: Endocyte's revenue is $10 Million to $25 Million

Answer: Endocyte's SIC: 2834

Answer: Endocyte's NAICS: 325412

Answer: Endocyte has 51-200 employees

Answer: Endocyte is in Pharmaceuticals

Answer: Endocyte contact info: Phone number: 76******** Website: https://endocyte.com

Answer: Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the personalized treatment of cancer. The company's drug conjugation technology targets therapeutics and companion imaging agents specifically to the site of diseased cells. Endocyte's lead program is a prostate specific membrane antigen (PSMA)-targeted radioligand therapy, 177Lu-PSMA-617, entering phase 3 for metastatic castration resistant prostate cancer (mCRPC). Endocyte is also advancing its adaptor-controlled CAR T-cell therapy into the clinic, where it will be studied in osteosarcoma.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access